Answers are grounded in this paper and cite their sources.
High Resolution Image Download MS PowerPoint Slide This study focuses on the synthesis of OA@ZnFe 2 O 4 NPs and the investigation of their structural, magnetic, and biological characteristics as well as their pH-responsive drug release behavior for potential biomedical use. The particles with an average particle size of ∼23 nm exhibited a single-phase spinel structure and superparamagnetic behavior. DOX was successfully loaded onto the NPs with a remarkably high efficiency (∼99%). In vitro release studies demonstrated that the OA@ZnFe 2 O 4 NPs exhibited a pH-dependent release behavior in phosphate-buffered saline and citrate buffers. The release rate was highest at pH 4.5, followed by pH 6.5 and then pH 7.4 in both buffer media. The OA@ZnFe 2 O 4 NPs (0.5 mg/mL) in citrate buffer at pH 4.5 demonstrated a markedly higher release efficiency, reaching approximately 77% cumulative release over ∼5 days. Cell imaging demonstrated efficient uptake of the DOX@OA@ZnFe 2 O 4 NPs in SH-SY5Y neuroblastoma cells. Biocompatibility assays showed that the OA@ZnFe 2 O 4 NPs were nontoxic to normal 3T3 fibroblasts, while the DOX@OA@ZnFe 2 O 4 NPs exhibited strong anticancer activity comparable to free DOX. These findings support the potential of the OA@ZnFe 2 O 4 NPs as a pH-sensitive nanocarrier for targeted neuroblastoma therapy with reduced systemic side effects.
No takes yet. Share an insight, caveat, or question.
Dönmez et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: